Novartis Venture Fund

Novartis Venture Fund (NVF) is a life-science venture fund that makes equity investments in biotechnology and biopharmaceutical companies across North America and Europe. NVF manages approximately USD 750 million, invests primarily at Seed and Series A stages (but may consider later-stage opportunities), typically invests USD 5–10 million per company with allocations up to USD 25 million, and takes an active, board-level role to support clinical and commercial development.

Novartis Venture Fund

Basel, Basel-Stadt, Switzerland, Europe

https://www.nvfund.com/

klydon@sosei.com

877 280 2296

Services

Equity investment

Provides equity capital to biotechnology and biopharmaceutical companies, typically USD 5–10 million with the ability to allocate up to USD 25 million to a single company.

Board participation and governance

Takes board seats and works closely with company leadership to provide governance, oversight and strategic input.

Active, hands-on operational and strategic support

Provides hands-on support drawing on NVF team experience in science, business development and drug development to help advance clinical and commercial objectives.

Due diligence and investment evaluation

Performs in-depth scientific, technical, financial and team evaluation prior to investment, followed by a thorough due diligence process.

Novartis Venture Fund